216 related articles for article (PubMed ID: 19069242)
1. Effects of epigallocatechin gallate on the bioavailability and pharmacokinetics of diltiazem in rats.
Li C; Choi JS
Pharmazie; 2008 Nov; 63(11):815-8. PubMed ID: 19069242
[TBL] [Abstract][Full Text] [Related]
2. Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats.
Hong SP; Choi DH; Choi JS
Cardiovasc Ther; 2008; 26(4):269-75. PubMed ID: 19035878
[TBL] [Abstract][Full Text] [Related]
3. Effect of atorvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats.
Hong SP; Chang KS; Choi DH; Choi JS
Arch Pharm Res; 2007 Jan; 30(1):90-5. PubMed ID: 17328247
[TBL] [Abstract][Full Text] [Related]
4. Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats.
Cho YA; Choi DH; Choi JS
J Pharm Pharmacol; 2009 Jun; 61(6):825-9. PubMed ID: 19505375
[TBL] [Abstract][Full Text] [Related]
5. Effects of morin pretreatment on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem in rats.
Choi HJ; Choi JS
Arch Pharm Res; 2005 Aug; 28(8):970-6. PubMed ID: 16178425
[TBL] [Abstract][Full Text] [Related]
6. Effects of lovastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats: possible role of cytochrome P450 3A4 and P-glycoprotein inhibition by lovastatin.
Hong SP; Yang JS; Han JY; Ha SI; Chung JW; Koh YY; Chang KS; Choi DH
J Pharm Pharmacol; 2011 Jan; 63(1):129-35. PubMed ID: 21189658
[TBL] [Abstract][Full Text] [Related]
7. Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats.
Choi JS; Han HK
Int J Pharm; 2005 Nov; 305(1-2):122-8. PubMed ID: 16226412
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral epigallocatechin gallate on the pharmacokinetics of nicardipine in rats.
Choi JS; Burm JP
Arch Pharm Res; 2009 Dec; 32(12):1721-5. PubMed ID: 20162400
[TBL] [Abstract][Full Text] [Related]
9. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
Choi DH; Choi JS; Li C; Choi JS
Pharmacol Rep; 2011; 63(6):1574-82. PubMed ID: 22358108
[TBL] [Abstract][Full Text] [Related]
10. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats.
Shin SC; Choi JS
Anticancer Drugs; 2009 Aug; 20(7):584-8. PubMed ID: 19491656
[TBL] [Abstract][Full Text] [Related]
11. Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats.
Chung JH; Choi DH; Choi JS
Biopharm Drug Dispos; 2009 Mar; 30(2):90-3. PubMed ID: 19226653
[TBL] [Abstract][Full Text] [Related]
12. Enhanced diltiazem bioavailability after oral administration of diltiazem with quercetin to rabbits.
Choi JS; Li X
Int J Pharm; 2005 Jun; 297(1-2):1-8. PubMed ID: 15907592
[TBL] [Abstract][Full Text] [Related]
13. Repeated dosing of piperine induced gene expression of P-glycoprotein via stimulated pregnane-X-receptor activity and altered pharmacokinetics of diltiazem in rats.
Qiang F; Kang KW; Han HK
Biopharm Drug Dispos; 2012 Nov; 33(8):446-54. PubMed ID: 22927137
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interaction between diltiazem and morin, a flavonoid, in rats.
Choi JS; Han HK
Pharmacol Res; 2005 Nov; 52(5):386-91. PubMed ID: 16002304
[TBL] [Abstract][Full Text] [Related]
15. Effects of green tea extract and (-)-epigallocatechin-3-gallate on pharmacokinetics of nadolol in rats.
Misaka S; Miyazaki N; Fukushima T; Yamada S; Kimura J
Phytomedicine; 2013 Nov; 20(14):1247-50. PubMed ID: 23920278
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of the calcium-channel blocker diltiazem after a single intravenous dose in horses.
Schwarzwald CC; Sams RA; Bonagura JD
J Vet Pharmacol Ther; 2006 Jun; 29(3):165-71. PubMed ID: 16669860
[TBL] [Abstract][Full Text] [Related]
17. Improved effectiveness of biochanin A as a P-gp inhibitor in solid dispersion.
Han HK; Lee HK
Pharmazie; 2011 Sep; 66(9):710-5. PubMed ID: 22026129
[TBL] [Abstract][Full Text] [Related]
18. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats.
Li C; Lee MY; Choi JS
Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320
[TBL] [Abstract][Full Text] [Related]
19. Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine.
Choi JS; Choi I; Choi DH
Pharmacol Rep; 2013; 65(5):1422-30. PubMed ID: 24399740
[TBL] [Abstract][Full Text] [Related]
20. Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats.
Choi JS; Choi JS; Choi DH
Pharmazie; 2013 Nov; 68(11):882-8. PubMed ID: 24380237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
